Reporter of the Economic Business: Xu Libo Editor of the Economic Business Business: Wei Guanhong
On October 16, the 20th National Congress of the Communist Party of China opened in Great Hall of the People . The Party Committee of Xiansheng Pharmaceutical organized party members from various branches to listen to and watch the grand event at the group headquarters.
In recent years, China's biomedical industry has been in full swing and opportunities are everywhere. Accelerate drug review and approval, shorten the medical insurance catalog cycle, and simple renewal of new indications without renegotiation. It has become an industry consensus to empower and benefit innovative drug business.
新年2新年年年年年3期年年年年年年年3期年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年年Xiansheng Pharmaceutical has built the "National Key Laboratory of Transformational Medicine and Innovative Drugs" approved by the Ministry of Science and Technology, focusing on the field of diseases that seriously threaten the health of the people, and developed a new drug called stroke with independent intellectual property rights, and obtained special support from the Ministry of Science and Technology "Major New Drug Creation" twice. Xianbixin has become the only new stroke drug in the world in the past seven years.
In addition, Xiansheng Pharmaceutical actively participated in the fight against the new crown epidemic, and developed a new crown 3CL target oral small molecule drug in cooperation with the Shanghai Institute of Drugs of the Chinese Academy of Sciences and others, exploring the application of anti-COVID treatment and prevention of new crown close contact populations after exposure. It has entered the third phase of clinical research. As the first domestic 3CL target oral drug to obtain clinical approval, it is expected to bring new breakthroughs to the fight against the epidemic.
Looking forward to the future, Xiansheng Pharmaceutical will continue to follow the path of high-quality development of , adhere to scientific and technological innovation, and under the new development pattern of domestic circulation as the main body and domestic and international dual circulation mutually promoting each other, embrace cooperation, collaborative innovation, build an open and innovative ecosystem, explore international layout and innovation, focus on breakthrough technologies in the three major fields of tumors, nervous system and autoimmune, and actively and forward-looking layout of disease fields with major clinical needs in the future, develop good medicines that the people can afford, and contribute to the construction of a healthy China.
Daily Economic News
